Laigneville, France

Laurent Courvoisier



 

Average Co-Inventor Count = 6.2

ph-index = 3

Forward Citations = 27(Granted Patents)


Company Filing History:


Years Active: 2006-2016

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovations of Laurent Courvoisier

Introduction

Laurent Courvoisier is a notable inventor based in Laigneville, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of optical enantiomers of modafinil. With a total of four patents to his name, Courvoisier's work has had a considerable impact on the industry.

Latest Patents

One of his latest patents is titled "Process for the preparation of and crystalline forms of optical enantiomers of modafinil." This invention relates to a polymorphic form of (−)-modafinil that produces a powder X-ray diffraction spectrum comprising intensity peaks corresponding to interplanar spacings of about 8.54, 4.56, and 3.78 Å. Another significant patent is focused on "Modafinil polymorphic forms," which includes polymorphic forms of modafinil racemate, methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment involving these polymorphic forms.

Career Highlights

Throughout his career, Courvoisier has worked with prominent companies in the pharmaceutical sector, including Cephalon France and Organisation De Synthese Mondiale Orsymonde. His expertise in the field has allowed him to contribute to various innovative projects and advancements.

Collaborations

Courvoisier has collaborated with notable individuals such as Franck Patrick Mallet and Véronique Broquaire, who serves as a Legal Representative. These collaborations have further enhanced his work and contributions to the field.

Conclusion

Laurent Courvoisier's innovative work in the development of modafinil and its polymorphic forms showcases his significant contributions to the pharmaceutical industry. His patents reflect a commitment to advancing therapeutic treatments and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…